Published in Blood Weekly, November 29th, 2001
Both mutations play a key role in the detection and risk assessment of certain cardiovascular disorders characterized by blood clot formation (thrombosis), potentially allowing preventive measures to be taken to reduce the chance for the onset of heart attack or stroke. This is the company's third internally validated research protocol. The anticipated users of the protocol include CLIA (Clinical Laboratory Improvement Act)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.